8-K: Silexion Therapeutics Announces Positive Initial Data for SIL204 in Pancreatic Cancer Models

Silexion Therapeutics reports that SIL204, administered subcutaneously, demonstrates efficacy in reducing both primary tumors and metastases in orthotopic pancreatic cancer models.

Summary

• Silexion Therapeutics announced positive data from orthotopic pancreatic cancer models, showing that subcutaneously administered SIL204 reduces both primary tumor growth and metastatic spread.
• The findings validate SIL204's efficacy in a clinically relevant setting where human pancreatic tumor cells are implanted directly into the pancreas.
• SIL204 showed robust activity across multiple pancreatic cancer cell lines with different KRAS mutation profiles.
• In AsPC-1 cells (KRAS G12D mutation), there was approximately a 70% reduction in overall bioluminescence by day 28 compared to the control group.
• In Panc-1 cells (KRAS G12D mutation), tumor cell numbers decreased dramatically in a dose-dependent manner, with the highest-dose group showing the most significant effect.
• Bioluminescence in the control group increased by over 100%, while in the SIL204 treated group it decreased by 12% compared to baseline by day 14 (P-value < 0.05).
• In BxPC-3 cells (KRAS wild-type model), there was approximately an 80% reduction in overall bioluminescence compared to the control group by day 28.
• SIL204 treatment significantly reduced metastatic spread to secondary organs, lowering metastatic burden across the liver, intestine, spleen, and stomach in Panc-1 and BxPC-3 models.
• Subcutaneous administration of SIL204 proved effective in reaching and treating pancreatic tumors and their metastases, confirming systemic delivery as a viable administration route.
• Silexion is actively exploring an expanded development plan for SIL204 using the systemic administration approach and expects to provide more detailed information in the coming weeks.

Sentiment

Score: 8

Explanation: The document presents positive initial data from preclinical studies, suggesting potential for SIL204 in treating pancreatic cancer. The management's comments are optimistic, and the company is actively exploring an expanded development plan. However, it's important to note that these are preclinical results, and further clinical trials are needed to confirm the efficacy and safety of SIL204.

Positives

• SIL204 shows significant efficacy in reducing primary tumor growth in orthotopic pancreatic cancer models.
• SIL204 demonstrates the ability to reduce metastatic spread to secondary organs.
• Subcutaneous administration of SIL204 is effective, suggesting a minimally-invasive delivery method.
• The company is actively exploring an expanded development plan for SIL204.

Risks

• The forward-looking statements involve risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied.
• Risks include the ability to successfully complete preclinical studies and initiate clinical trials, the impact of the regulatory environment, and the company's future capital requirements.

Future Outlook

Silexion is actively exploring an expanded development plan for SIL204 using the systemic administration approach and expects to provide more detailed information in the coming weeks.

Management Comments

• Mitchell Shirvan, Ph.D., CSO of Silexion, stated that the orthotopic model results represent a pivotal advancement in their development program and provide initial validation of SIL204's potential effectiveness in a more clinically relevant setting.
• Ilan Hadar, Chairman and CEO of Silexion, added that the ability to deliver their therapy systemically and still effectively target both primary pancreatic tumors and their metastases represents a significant potential advantage for treating this devastating disease.

Industry Context

Pancreatic cancer is a difficult-to-treat cancer with a high mortality rate, and new therapies are needed. Silexion's approach of targeting KRAS mutations with RNAi therapies represents a promising avenue for treatment.

Comparison to Industry Standards

• The use of orthotopic models is considered a more clinically relevant approach compared to subcutaneous xenograft models, as it better mimics human disease progression.
• Other companies developing therapies for pancreatic cancer include companies such as Roche, Novartis, and Eli Lilly, but Silexion's focus on RNAi and KRAS mutations differentiates its approach.
• The reported reduction in tumor growth and metastasis with SIL204 is encouraging and warrants further investigation in clinical trials.

Stakeholder Impact

• Positive results could lead to improved treatment options for patients with pancreatic cancer.
• Successful development of SIL204 could increase shareholder value.
• The company's progress may attract potential partners and investors.

Next Steps

• Silexion is actively exploring an expanded development plan for SIL204 using the systemic administration approach.
• The Company is finalizing an updated development strategy that leverages these new findings and expects to provide more detailed information in the coming weeks.

Key Dates